表紙
市場調查報告書

關注市場分析:皮膚T細胞淋巴瘤 (CTCL)

Market Spotlight: Cutaneous T-Cell Lymphoma (CTCL)

出版商 Datamonitor Healthcare 商品編碼 603905
出版日期 內容資訊 英文 45 Pages
商品交期: 最快1-2個工作天內
價格
關注市場分析:皮膚T細胞淋巴瘤 (CTCL) Market Spotlight: Cutaneous T-Cell Lymphoma (CTCL)
出版日期: 2020年07月21日內容資訊: 英文 45 Pages
簡介

全球皮膚T細胞淋巴瘤 (CTCL)的發病數預計從2016年的約13,600件,至2025年增加到16,100件。

本報告提供全球皮膚T細胞淋巴瘤 (CTCL)的治療藥的市場調查,疾病的背景、概要,發病數的十年預測,主要的治療方法,已上市藥物及藥物開發平台趨勢,授權、資產收購等企業間的主要交易趨勢,專利資訊,臨床試驗狀況等彙整資料。

要點

疾病的背景

  • 亞型

治療

  • 局部療法 (Skin-directed therapy:SDT)
  • 全身療法 (Systemic therapy:ST)

流行病學

已上市藥物

  • 核准:各國

開發平台藥物

今後主要的活動

授權、資產收購等的交易

本源專利

商機

臨床試驗環境

  • 贊助商:各進展狀況
  • 贊助商:各階段
  • 近幾年的活動

文獻

  • 處方資訊

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0183413

This Market Spotlight report covers the Cutaneous T-Cell Lymphoma (CTCL) market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, recent events and analyst opinion, probability of success, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2017, there were approximately 15,200 incident cases of cutaneous T-cell lymphoma (CTCL) worldwide, and forecasts that number to increase to 18,060 incident cases by 2026.

In 2017, there were approximately 5,930 incident cases of CTCL in the US and five major European markets (France, Germany, Italy, Spain and the UK), which is forecast to increase to 6,160 incident cases by 2026

Datamonitor Healthcare estimates that there were approximately 41,900 10-year prevalent cases of CTCL in the US and five major European markets in 2017, which is expected to increase to 45,030 cases by 2026.

Approved drugs in the CTCL space target antibody-drug conjugate, cluster of differentiation 30, tumor necrosis factor receptor superfamily member 8, microtubules, histone deacetylase, interleukin-2, protein synthesis, chemokine receptor 4, retinoid X receptors, retinoid receptors, DNA, and DNA synthesis. These drugs are administered via the intravenous, topical, and oral routes.

The majority of industry-sponsored drugs in active clinical development for CTCL are in Phase II, with only one drug in Phase III. Therapies in development for CTCL focus on a wide variety of targets. The greatest proportion of pipeline drugs in development are administered intravenously, with the remainder being tested in oral, topical, intratumoral, and subcutaneous formulations.

High-impact upcoming events for drugs in the CTCL space comprise topline Phase II trial results for resminostat, AFM13, IPH4102, and cobomarsen.

The overall likelihood of approval of a Phase I hematologic asset is 10%, and the average probability a drug advances from Phase III is 61.6%. Drugs, on average, take 9.1 years from Phase I to approval, compared to 9.3 years in the overall oncology space.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for CTCL have been in the early and mid-phases of development, with 88% of trials in Phase I-II, and only 12% in Phase III-IV.

The US has a substantial lead in the number of CTCL clinical trials globally. Germany leads the major European markets, while Japan has the top spot in Asia. * Clinical trial activity in the CTCL space is dominated by completed trials. Bristol Myers Squibb has the highest number of completed clinical trials for CTCL, with six trials. Bristol Myers Squibb also leads the industry sponsors with the highest overall number of clinical trials for CTCL, followed by Merck & Co

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

  • Skin-directed therapy
  • Systemic therapy

EPIDEMIOLOGY

  • Incidence methodology for the US and five major European markets
  • Prevalence methodology for the US and five major European markets

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • SGX301 for CTCL (April 30, 2020)
  • SGX301 for CTCL (March 19, 2020)
  • Copiktra for CTCL (July 25, 2019)
  • Copiktra for CTCL (March 6, 2019)
  • Multiple Drugs for CTCL (January 17, 2019)

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Almirall Gets Option To Buy Bioniz, Partners With 23andMe

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Global trends in incident cases of CTCL, 2017-26
  • Figure 2: Trends in incident cases of CTCL, US and 5 Euro, 2017-26
  • Figure 3: Overview of pipeline drugs for CTCL in the US
  • Figure 4: Pipeline drugs for CTCL, by company
  • Figure 5: Pipeline drugs for CTCL, by drug type
  • Figure 6: Pipeline drugs for CTCL, by classification
  • Figure 7: SGX301 for CTCL (April 30, 2020): Phase III - FLASH
  • Figure 8: SGX301 for CTCL (March 19, 2020): Phase III - FLASH
  • Figure 9: Key upcoming events in CTCL
  • Figure 10: Probability of success in the CTCL pipeline
  • Figure 11: Clinical trials in CTCL
  • Figure 12: Top 10 drugs for clinical trials in CTCL
  • Figure 13: Top 10 companies for clinical trials in CTCL
  • Figure 14: Trial locations in CTCL
  • Figure 15: CTCL trials status
  • Figure 16: CTCL trials sponsors, by phase

LIST OF TABLES

  • Table 1: Global incident cases of CTCL, 2017-26
  • Table 2: Incident cases of CTCL, US and 5 Euro, 2017-26
  • Table 3: 10-year prevalent cases of CTCL, US and 5 Euro, 2017-26
  • Table 4: Five-year prevalent cases of CTCL, US and 5 Euro, 2017-26
  • Table 5: Marketed drugs for CTCL
  • Table 6: Pipeline drugs for CTCL in the US
  • Table 7: SGX301 for CTCL (April 30, 2020)
  • Table 8: SGX301 for CTCL (March 19, 2020)
  • Table 9: Copiktra for CTCL (July 25, 2019)
  • Table 10: Copiktra for CTCL (March 6, 2019)
  • Table 11: Multiple Drugs for CTCL (January 17, 2019)
  • Table 12: Historical global sales, by drug ($m), 2015-19
  • Table 13: Forecasted global sales, by drug ($m), 2020-24